<DOC>
	<DOCNO>NCT00000919</DOCNO>
	<brief_summary>The purpose study compare effectiveness various combination anti-HIV drug HIV-positive men woman . Patients receive specific combination 3 4 follow 6 drug : didanosine ( ddI ) , stavudine ( d4T ) efavirenz ( EFV ) , nelfinavir ( NFV ) , lamivudine ( 3TC ) , zidovudine ( ZDV ) . Anti-HIV therapy effective prevent spread HIV body . However , patient often experience unpleasant side effect difficulty follow dosing schedule . This study look combination anti-HIV drug ( `` cocktail '' ) effective few problem .</brief_summary>
	<brief_title>A Study Evaluate Various Combinations Anti-HIV Medications Treat Early HIV Infection</brief_title>
	<detailed_description>Highly active antiretroviral therapy , though effective suppression HIV proliferation , often complicate difficulty adherence drug toxicity . Various combination highly active antiretroviral therapy exist ; prove efficacious related trial . The question address trial combination antiretroviral `` cocktail '' provide single great advantage prevent spread HIV body . In effect , therapy provide great benefit few complication . Step 1 : Patients randomize 1 6 arm : Arm A : didanosine ( ddI ) , stavudine ( d4T ) , efavirenz ( EFV ) , nelfinavir ( NFV ) placebo . Arm B : ddI , d4T , EFV placebo , NFV . Arm C : lamivudine ( 3TC ) /zidovudine ( ZDV ) , EFV , NFV placebo . Arm D : 3TC/ZDV , EFV placebo , NFV . Arm E : ddI , d4T , EFV , NFV . Arm F : 3TC/ZDV , EFV , NFV . Patients virologic failure 2 successive measurement study-drug intolerance discontinue randomize study therapy proceed Step 2 . [ AS PER AMENDMENT 7/5/00 : Patients must switch regimen soon possible confirmation virologic failure prevent development drug resistance . ] Step 2 : Arm A : Patients receive treatment Arm D Step 1 . Arm B : Patients receive treatment Arm C Step 1 . Arm C : Patients receive treatment Arm B Step 1 . Arm D : Patients receive treatment Arm A Step 1 . Arms A , B , C , D : Patients fail Step 2 treatment proceed Step 3 . Arms E F : Patients virologic failure Step 1 proceed immediately Step 3 . Step 3 ( salvage therapy ) : Arm A , B , C , D : Patients receive indinavir ( IDV ) , amprenavir ( APV ) , ddI , hydroxyurea ( HU ) . [ AS PER AMENDMENT 7/5/00 : Patients receive treatment Regimen 1 , 2 , 3 , 4 , 5 , 6 . Regimen 1 consists IDV , ritonavir ( RTV ) , ddI , HU . Regimen 2 consist APV , RTV , ddI , HU . Regimen 3 consist IDV , RTV , abacavir ( ABC ) , 3TC/ZDV . Regimen 4 consists APV , RTV , ABC , 3TC/ZDV . Regimen 5 consists IDV , RTV , ABC , d4T , 3TC . Regimen 6 consists APV , RTV , ABC , d4T , 3TC . ] Arm E : Patients receive IDV , APV , 3TC/ZDV . [ AS PER AMENDMENT 7/5/00 : Patients receive treatment Regimen 7 8 . Regimen 7 consists IDV , RTV , 3TC/ZDV . Regimen 8 consists APV , RTV , 3TC/ZDV . ] Arm F : Patients receive IDV , APV , ddI , d4T . [ AS PER AMENDMENT 7/5/00 : Patients receive treatment Regimen 9 10 . Regimen 9 consists IDV , RTV , ddI , d4T . Regimen 10 consists APV , RTV , ddI , d4T . ] [ AS PER AMENDMENT 7/5/00 : Patients already enrol Step 3 site registration Version 4.0 protocol option receive 1 appropriate new Step 3 regimen outline stay originally assign Step 3 therapy . ] [ AS PER AMENDMENT 3/21/01 : If virologic failure Step 1 2 confirm , HIV-1 RNA genotype resistance test ( real-time , possible ) perform . Patients receive 1 Step 3 drug regimen base result resistance test . ] Patients may co-enroll metabolic , pharmacologic , immunologic , adherence substudies .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : [ Required : AS PER AMENDMENT 7/5/00 : Chemoprophylaxis Pneumocystis carinii pneumonia CD4+ cell count less equal 200 cells/mm3 . ] [ Suggested alternative agent chemoprophylaxis Mycobacterium avium complex : Azithromycin . ] [ Allowed : AS PER AMENDMENT 7/5/00 : Topical oral antifungal agent . Oral itraconazole may administer concurrently IDV dose IDV reduce 600 mg every 8 hour . Treatment , maintenance , chemoprophylaxis opportunistic infection , clinically indicate unless otherwise prohibit protocol . All antibiotic , clinically indicate unless otherwise prohibit protocol . Systemic corticosteroid use 21 day less acute problem , medically indicate . Recombinant erythropoietin ( rEPO , epoetin alfa , Epogen , epoetin beta , Marogen ) , granulocyte colonystimulating factor ( GCSF , filgrastim , Neupogen ) , granulocytemacrophage colonystimulating factor ( GMCSF , Regramostim ) . Regularly prescribed medication , antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , megestrol acetate ( Megace ) , testosterone , medication , medically indicate unless otherwise prohibit protocol . NOTE : Due possibility study medication may alter effectiveness oral contraceptive depoprogesterone , agent must use sole form birth control , role study medication effectiveness method yet establish . Alternative therapy , vitamin . Medications require low gastric pH administer time buffer ddI . Patients take agent least 2 hour ddI . ] Vaccinations , administer least 2 week prior HIV RNA viral load evaluation . [ Allowed caution : AS PER AMENDMENT 7/5/00 : Oral ketoconazole IDV . Medications interact PIs substrate , inhibitor , inducer , include , limited : allopurinol , alprazolam , amitriptyline , atorvastatin , bupropion , carbamazepine , cerivastatin , chlorpheniramine , chlorpromazine , chlorzoxazone , cimetidine , clarithromycin , clofibrate , clorazepate , clozapine , codeine , dapsone , desipramine , diazepam , diltiazem , disopyramide , encainide , erythromycin , estazolam , estrogens progesterone , fluoxetine , flurazepam , fluvastatin , glucocorticoid , hypericum perforatum ( St. John 's wort ) , imipramine , isoniazid , itraconazole , ketoconazole , labetalol , lamotrigine , lidocaine , lovastatin , mexiletine , morphine , naloxone , nefazodone , nifedipine , nortriptyline , opioids , oxazepam , pentazocine , phenobarbital , phenytoin , promethazine , propofol , propranolol beta blocker , sildenafil , simvastatin , temazepam , T3 ( thyroid hormone ) , warfarin , valproic acid , zolpidem . Drugs high proteinbinding property , nephrotoxic drug , opiate agonist ( e.g. , methadone buprenorphine ) . ] NOTE : Refer package insert potential drug interaction IDV , RTV , NFV , APV may require therapeutic drug monitoring and/or adjustment concomitant medication . ] [ Allowed extreme caution : AS PER AMENDMENT 7/5/00 : ddI , clinically indicated patient know risk factor , include , limited , alcohol abuse , morbid obesity , hypertriglyceridemia , cholelithiasis , endoscopic retrograde cholangiopancreatography , use medication know cause pancreatitis ( e.g. , pentamidine ) use medication know thought increase exposure ddI ( e.g. , HU , allopurinol ) . ] Concurrent Treatment : [ Allowed : AS PER AMENDMENT 7/5/00 : Acupuncture visualization technique . ] Patients must : HIV infection , document licensed ELISA test kit confirm either Western blot , HIV culture , HIV antigen , plasma HIV1 RNA , second antibody test method ELISA time prior study entry . Plasma HIV1 RNA 500 copies/ml , confirm Roche Amplicor assay perform within 60 day [ AS PER AMENDMENT 5/5/99 : 70 day ] study entry certify laboratory . Inclusion laboratory parameter , document within 14 day prior study entry ( see lab value ) . [ AS PER AMENDMENT 9/9/99 : Coenrollment ACTG A5005s ( Metabolism Substudy ) require patient enrol Version 3.0 ACTG 384 . ] Risk Behavior : [ Allowed caution : AS PER AMENDMENT 7/5/00 : Alcoholic beverage . ] Exclusion Criteria Coexisting Condition : Patients follow condition exclude : AIDSrelated malignancy minimal Kaposi 's sarcoma . Concurrent Medication : [ Excluded : AS PER AMENDMENT 7/5/00 : Chronic systemic corticosteroid . For Steps 1 2 , antiretroviral therapy study medication . For step 3 , contact team discuss potential addition substitution offstudy antiretroviral medication . Investigational drug without specific approval study chair . Neurotoxic pancreatotoxic drug . Systemic cytotoxic chemotherapy . Amiodarone , astemizole , bepridil , cisapride , cholestyramine , ergot ergot derivative , flecainide , ganciclovir , interferon alfa , midazolam ( unless use sedation ACTG 723 ) , pimozide , propafenone , propoxyphene , quinidine , ribavirin , rifampin , sucralfate , terfenadine , triazolam . Rifabutin patient RTV Step 3 patient Steps 1 2 contradictory effect EFV NFV plasma rifabutin level . If patient Step 1 2 require treatment rifabutin come study , team must notify . Alpha tocopherol ( vitamin E ) supplementation since vitamin E contain soft gelatin capsule formulation APV . ddI concurrently IV pentamidine . Herbal medication . ] Patients follow prior condition exclude : Pancreatitis within 3 year study entry . Current peripheral neuropathy grade 2 great history peripheral neuropathy grade 3 great . Documented suspect acute hepatitis within 30 day prior study entry . Unexplained temperature 38.5 C 7 day chronic diarrhea ( defined 3 liquid stool per day persist 15 day ) within 30 day prior study entry . Any previous hypersensitivity study drug component . Prior Medication : Excluded : Receipt within 30 day erythropoietin , GCSF , GMCSF . Treatment within 14 day study entry following : amiodarone , astemizole , cisapride , ergot ergot derivative , ketoconazole , midazolam , propoxyphene , quinidine , rifampin , terfenidine , triazolam . Prior antiretroviral therapy 7 day , include protease inhibitor ( PIs ) , nucleoside reverse transcriptase inhibitor ( NRTIs ) , nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) . [ AS PER AMENDMENT 5/5/99 : Systemic ketoconazole itraconazole , intravenous pentamidine , rifabutin prohibit . Midazolam allow sedation patient participate ACTG 723 . ] Any vaccination within 14 day prior study entry . Any immunomodulator investigational therapy within 30 day prior study entry . [ AS PER AMENDMENT 5/5/99 : 6 . Rifabutin discourage . ] Prior Treatment : Excluded : Acute therapy infection medical illness within 14 day prior study entry . [ AS PER AMENDMENT 5/5/99 : Acute therapy serious infection serious medical illness potentially lifethreatening require systemic therapy and/or hospitalization within 14 day study entry . Patients Pneumocystis carinii pneumonia must complete acute therapy least 7 day prior entry clinically stable . Patients serious infection serious medical illness must continue chronic therapy must complete least 14 day therapy prior entry clinically stable . Patients infection medical illness must complete therapy , least 14 day maintenance therapy , prior entry clinically stable ( restriction apply oral vaginal candidiasis , mucocutaneous herpes simplex infection , minor skin condition ) . ] Risk Behavior : Excluded : Possible current substance abuse could prevent compliance study medication .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>